Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Feasibility and Effectiveness of an AI-Powered Carbohydrate Counting Educational Platform to Support Parents of Children With Type 1 Diabetes (CARB-AI)

26. června 2026 aktualizováno: Dr. Hussain Al Saffar, Sultan Qaboos University

Feasibility and Effectiveness of an AI-Powered Carbohydrate Counting Educational Platform to Support Parents of Children With Type 1 Diabetes: A Multicentre Randomized Controlled Trial

The goal of this clinical trial is to learn whether an AI-powered carbohydrate counting educational platform can help parents of children with type 1 diabetes improve their carbohydrate counting skills and diabetes management. The study will include parents or primary caregivers of children aged 2-12 years with type 1 diabetes.

The main questions it aims to answer are:

  • Is the AI-powered educational platform feasible, acceptable, and easy for parents to use?
  • Can the platform improve carbohydrate counting accuracy, parental confidence in diabetes management, and diabetes outcomes compared with usual education alone?

Researchers will compare parents who receive access to the AI-powered carbohydrate counting educational platform plus usual diabetes education with parents who receive usual diabetes education alone to see whether the AI-supported approach provides additional benefits.

Participants will:

  • Complete baseline assessments, including questionnaires and a carbohydrate counting test.
  • Be randomly assigned to either the AI-supported education group or the usual education group.
  • Use the assigned educational resources for 12 weeks.
  • Complete a follow-up assessment at 6 weeks and a final assessment at 12 weeks.
  • Provide information about their child's diabetes management, including HbA1c and glucose monitoring data.
  • Complete questionnaires about confidence, usability, and satisfaction with the educational support they receive.

The AI platform is designed to provide educational support only and does not replace medical advice, insulin dosing decisions, or routine diabetes care provided by healthcare professionals.

Přehled studie

Detailní popis

This multicentre randomized controlled feasibility trial will evaluate an AI-powered educational platform designed to support carbohydrate counting education for parents of children with type 1 diabetes (T1D). Accurate carbohydrate counting is an essential component of T1D management because insulin dosing is closely linked to carbohydrate intake. However, many parents experience challenges in estimating carbohydrate content accurately, which may affect glycemic control.

The intervention uses conversational artificial intelligence to provide personalized educational support, interactive learning opportunities, and practical guidance related to carbohydrate counting. The platform is intended as an educational tool and does not provide medical advice or insulin dosing recommendations. Educational content and safety oversight are provided by pediatric endocrinologists, diabetes educators, and registered dietitians.

The primary objective of this feasibility study is to evaluate recruitment, retention, participant engagement, intervention adherence, and data collection procedures to determine whether a future definitive efficacy trial is warranted. Secondary objectives include assessment of participant acceptability and usability, as well as exploration of preliminary effects on carbohydrate counting accuracy, parental diabetes management self-efficacy, and glycemic outcomes.

Participants will be recruited from our pediatric diabetes centers, and randomized to receive either access to the AI-powered educational platform in addition to enhanced usual care or enhanced usual care alone. Study findings will inform the development of larger trials evaluating the role of conversational artificial intelligence in diabetes education and chronic disease self-management.

Typ studie

Intervenční

Zápis (Odhadovaný)

80

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

  • Jméno: Hussain Alsaffar, FACE, MSc, FRCPCH
  • Telefonní číslo: +96896399402
  • E-mail: hussaina@squ.edu.om

Studijní místa

      • Muscat, Omán, 123
        • Sultan Qaboos University Hospital
      • Dubai, Spojené arabské emiráty
        • Al Jalila Children's Hospital
      • Sharjah city, Spojené arabské emiráty
        • Al Qasimi Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dítě
  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Primary responsibility for carbohydrate counting and insulin dosing decisions for the child
  • English-speaking
  • Access to a smartphone (iOS or Android) with internet connectivity
  • Willing and able to provide informed consent and complete study procedures
  • Diagnosis of type 1 diabetes for at least 1 month
  • Receiving intensive insulin therapy (multiple daily injections or insulin pump)
  • Using carbohydrate counting for insulin dosing

Exclusion Criteria:

  • Child has significant developmental delay or a medical condition that substantially alters nutritional requirements or carbohydrate metabolism (e.g., celiac disease, cystic fibrosis)
  • Parent or caregiver has significant cognitive impairment that would preclude participation
  • Family plans to relocate from the study area during the study period
  • Participation in another diabetes intervention study

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Podpůrná péče
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: AI-Powered Carbohydrate Counting Educational Platform + Enhanced Usual Care
Participants receive access to an AI-powered carbohydrate counting educational platform in addition to enhanced usual diabetes care. The platform provides interactive educational support, carbohydrate counting practice, personalized feedback, scenario-based learning, and educational guidance under dietitian and diabetes specialist oversight. Participants also receive standard diabetes education materials and routine clinical care for 12 weeks.
Participants will receive access to an AI-powered carbohydrate counting educational platform designed for parents of children with type 1 diabetes. The platform provides interactive carbohydrate counting education, personalized educational guidance, carbohydrate estimation practice, natural-language question answering, and scenario-based learning. Participants will use the platform for 12 weeks in addition to enhanced usual diabetes care. All educational content is developed and supervised by pediatric endocrinologists, certified diabetes educators, and registered dietitians. The platform functions as an educational support tool only and does not provide medical advice or insulin dosing recommendations.
Žádný zásah: Enhanced Usual Care Alone
Participants receive enhanced usual diabetes care consisting of standard diabetes education provided by their clinical care team, printed carbohydrate counting educational materials, portion size reference materials, educational PDF resources, and routine clinical care. Participants do not receive access to the AI-powered carbohydrate counting educational platform

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Recruitment Rate
Časové okno: 12 months
Number and proportion of eligible participants recruited into the study across participating sites.
12 months
Retention Rate
Časové okno: 12 weeks
Proportion of enrolled participants who complete the 12-week follow-up assessment.
12 weeks
Intervention Adherence
Časové okno: 12 weeks
Proportion of participants in the intervention group who engage with the AI-powered carbohydrate counting educational platform for at least 10 sessions during the study period.
12 weeks
Data Completeness
Časové okno: 12 weeks
Proportion of participants with complete primary outcome data collected at baseline and 12-week follow-up assessments.
12 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Acceptability of Intervention Measure
Časové okno: 12 weeks
Participant-rated acceptability of the AI-powered carbohydrate counting educational platform using the validated 4-item Acceptability of Intervention Measure.
12 weeks
Carbohydrate Counting Accuracy
Časové okno: Baseline and 12 weeks
Change in carbohydrate counting accuracy assessed using a standardized carbohydrate counting assessment. Accuracy will be defined as the percentage of estimates within 20% of dietitian-calculated carbohydrate values.
Baseline and 12 weeks
Time in Range (70-180 mg/dL)
Časové okno: Baseline and 12 weeks
Percentage of time glucose values remain within the target range of 70-180 mg/dL based on continuous glucose monitoring or glucose meter data.
Baseline and 12 weeks
Glucose Variability
Časové okno: Baseline and 12 weeks
Change in glucose variability measured by coefficient of variation of glucose values.
Baseline and 12 weeks
System Usability Scale
Časové okno: 12 weeks
Participant-rated usability of the AI-powered carbohydrate counting educational platform measured using the System Usability Scale (SUS), a validated 10-item questionnaire. The SUS total score ranges from 0 to 100, with higher scores indicating better perceived usability.
12 weeks
Net Promoter Score
Časové okno: 12 weeks
Participant likelihood of recommending the AI-powered carbohydrate counting educational platform to other parents of children with type 1 diabetes, measured using the Net Promoter Score (NPS). Participants rate their likelihood of recommending the platform on a scale from 0 (Not at all likely) to 100 (Extremely likely). Higher scores indicate a greater likelihood of recommending the intervention.
12 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Studijní židle: Moez AlIslam Faris, PhD, Applied Science Private University

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. září 2026

Primární dokončení (Odhadovaný)

31. srpna 2027

Dokončení studie (Odhadovaný)

31. prosince 2027

Termíny zápisu do studia

První předloženo

22. června 2026

První předloženo, které splnilo kritéria kontroly kvality

22. června 2026

První zveřejněno (Aktuální)

26. června 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

30. června 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

26. června 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit